Prophylactic platelet transfusions in patients with haematological malignancies – lessons from the TOPPS trial
People with haematological malignancies are the largest patient group who use platelet components, and platelet transfusions are an important supportive therapy during treatment with chemotherapy or haematopoietic stem cell transplantation (HSCT).
Main Author: | Estcourt, L |
---|---|
Format: | Conference item |
Published: |
Wiley
2016
|
Similar Items
-
Platelet transfusions for patients with haematological malignancies: who needs them?
by: Estcourt, L, et al.
Published: (2011) -
Prophylactic platelet transfusions
by: Estcourt, L, et al.
Published: (2010) -
Alternatives to prophylactic platelet transfusions
by: Estcourt, L
Published: (2016) -
Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation
by: Desborough, M, et al.
Published: (2016) -
Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial.
by: Campbell, H, et al.
Published: (2014)